DelveInsight’s, “Chronic Myelocytic Leukemia Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Chronic Myelocytic Leukemia pipeline landscape. It covers the Chronic Myelocytic Leukemia pipeline drug profiles, including Chronic Myelocytic Leukemia clinical trials and nonclinical stage products. It also covers the Chronic Myelocytic Leukemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Recent Developmental Activities in the Chronic Myelocytic Leukemia Treatment Landscape

 

• In February 2023, The FDA has given Dasynoc an ODD for the treatment of ALL and CML. The company anticipates receiving FDA approval by the time the product is launched in the United States in the second half of 2023.

 

• In March 2022, Inhibikase Therapeutics provided a reported update on IkT-001Pro, the Company’s prodrug formulation of Imatinib mesylate, designed as a potentially safer, better-tolerated treatment for Imatinib-sensitive cancers such as stable-phase Chronic Myeloid Leukemia (CML). The Company is completing clinical batch manufacturing of pill formulated IkT-001Pro and conducting required stability studies and expects to submit the IND for IkT-001Pro in the second quarter of 2022. IkT-001Pro has received Orphan Drug Designation for stable-phase Chronic Myeloid Leukemia and will follow the development pathway for FDA Approval through the 505(b) (2) regulation.

 

Request a sample and discover the recent breakthroughs happening in the Chronic Myelocytic Leukemia Pipeline landscape @ Chronic Myelocytic Leukemia Pipeline Outlook

 

Chronic Myelocytic Leukemia Overview

Chronic Myelocytic Leukemia (CML) (CMML) is a form of leukemia that is characterized by high numbers of white blood cells, called ‘monocytes’, in the blood and bone marrow. CMML is an uncommon blood cancer with features of two other types of blood cancer. Even though it has leukemia as part of its name, the World Health Organization (WHO) classifies CMML as a ‘mixed myelodysplastic (MDS) myeloproliferative neoplasm (MPN)’.

 

Key Takeaways from the Chronic Myelocytic Leukemia Pipeline Report

 

• DelveInsight’s Chronic Myelocytic Leukemia Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Chronic Myelocytic Leukemia treatment.

 

• The leading Chronic Myelocytic Leukemia Companies include Novarits Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, Chroma Therapeutics, Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda Oncology, Argenx, Kura Oncology, Incyte Corporation, Genentech, Inc., Sensei Biotherapeutics, Pfizer, BioLite, Inc., Newave Pharmaceutical Inc, Ellipses Pharma, Eli Lilly and Company, Aprea Therapeutics, Treadwell Therapeutics, Prelude Therapeutics, Onconova Therapeutics, Immune Pharmaceuticals, Teva Pharmaceutical Industries, and others

 

• Promising Chronic Myelocytic Leukemia Pipeline Therapies include Bosutinib, imatinib, Nilotinib, Asciminib, Dasatinib Tablets, interferon-alpha (INF-a), cytarabine (ARA-C), and others

 

• The Chronic Myelocytic Leukemia companies and academics are working to assess challenges and seek opportunities that could influence Chronic Myelocytic Leukemia (CML) R&D. The Chronic Myelocytic Leukemia therapies under development are focused on novel approaches to treat/improve Chronic Myelocytic Leukemia (CML).

 

For further information, refer to the detailed Chronic Myelocytic Leukemia Drugs Launch, Chronic Myelocytic Leukemia Developmental Activities, and Chronic Myelocytic Leukemia News, click here for Chronic Myelocytic Leukemia Ongoing Clinical Trial Analysis

 

Chronic Myelocytic Leukemia Emerging Drugs Profile

 

• Sabatolimab: Novarits Oncology

Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. The drug is currently in phase III stage of development for the treatment of Chronic Myelocytic Leukemia (CML).

 

• Enasidenib: Servier

Enasidenib (AG 221) is a small molecule, oral inhibitor of isocitrate dehydrogenase 2 (IDH2), being developed by Servier. The drug is currently in phase I stage of development for the treatment of Chronic Myelocytic Leukemia (CML).

 

Chronic Myelocytic Leukemia Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Chronic Myelocytic Leukemia (CML). The companies which have their Chronic Myelocytic Leukemia (CML) drug candidates in the most advanced stage, i.e. phase III include, Novarits Oncology.

 

Find out more about the Chronic Myelocytic Leukemia Pipeline Segmentation, Therapeutics Assessment, and Chronic Myelocytic Leukemia Emerging Drugs @ Chronic Myelocytic Leukemia Treatment Landscape

 

Scope of the Chronic Myelocytic Leukemia Pipeline Report

 

• Coverage- Global

 

• Chronic Myelocytic Leukemia Companies- Novarits Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, Chroma Therapeutics, Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda Oncology, Argenx, Kura Oncology, Incyte Corporation, Genentech, Inc., Sensei Biotherapeutics, Pfizer, BioLite, Inc., Newave Pharmaceutical Inc, Ellipses Pharma, Eli Lilly and Company, Aprea Therapeutics, Treadwell Therapeutics, Prelude Therapeutics, Onconova Therapeutics, Immune Pharmaceuticals, Teva Pharmaceutical Industries, and others

 

• Chronic Myelocytic Leukemia Pipeline Therapies- Bosutinib, imatinib, Nilotinib, Asciminib, Dasatinib Tablets, interferon-alpha (INF-a), cytarabine (ARA-C), and others

 

• Chronic Myelocytic Leukemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Chronic Myelocytic Leukemia Pipeline Companies and Therapies, click here @ Chronic Myelocytic Leukemia Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Myelocytic Leukemia (CML): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Myelocytic Leukemia (CML) – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Chronic Myelocytic Leukemia (CML) Collaboration Deals
9. Late Stage Products (Phase III)
10. Sabatolimab: Novartis
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Tefinostat: Chroma Therapeutics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Enasidenib: Servier
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Chronic Myelocytic Leukemia (CML) Key Companies
20. Chronic Myelocytic Leukemia (CML) Key Products
21. Chronic Myelocytic Leukemia (CML)- Unmet Needs
22. Chronic Myelocytic Leukemia (CML)- Market Drivers and Barriers
23. Chronic Myelocytic Leukemia (CML)- Future Perspectives and Conclusion
24. Chronic Myelocytic Leukemia (CML) Analyst Views
25. Chronic Myelocytic Leukemia (CML) Key Companies
26. Appendix

 

Got Queries? Find out the related information on Chronic Myelocytic Leukemia Mergers and acquisitions, Chronic Myelocytic Leukemia Licensing Activities @ Chronic Myelocytic Leukemia Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/